{"contentid": 488751, "importid": NaN, "name": "Akili bags $160 million in financing; poised to deliver on digital therapeutics", "introduction": "USA-headquartered digital medicines company Akili Interactive, maker of EndeavorRx, the first and only prescription video game treatment, today announced $160 million in combined equity and debt financing.", "content": "<p>USA-headquartered digital medicines company Akili Interactive, maker of EndeavorRx, the first and only prescription video game treatment, today announced $160 million in combined equity and debt financing.</p>\n<p>Akili is a pioneer of a new class of medicine and treatments that are not only effective and clinically-validated but that deliver amazing experiences to patients. The company&rsquo;s flagship product made history in June 2020 when it received US Food and Drug Administration and European Medicines Agency clearance. With the completion of the oversubscribed Series D financing, Akili will continue to push the boundaries of traditional medicine to deliver on the promise of digital therapeutics for patients.</p>\n<p>This funding will support a go-to market approach that brings&nbsp;<a href=\"https://www.endeavorrx.com/\">EndeavorRx</a>&nbsp;to families and healthcare professionals at scale and expand Akili&rsquo;s global footprint within attention-deficit/hyperactivity disorder (ADHD) and beyond. The financing will also enable Akili to build on the success of its patented technology platform, which has shown positive results in clinical trials across a number of indications, and further advance its pipeline of prescription digital therapeutics (PDTs) targeting a range of chronic and acute cognitive disorders.</p>\n<p>&ldquo;Akili is a leader in the digital therapeutics industry, setting the standard for clinical validation and advancing innovative medicine that challenges the imagination,&rdquo; said Gabe Cahill, managing director of Neuberger Berman, which led the oversubscribed $110 million Series D financing, adding: &ldquo;We are excited to partner with Akili as the company continues to break new ground with innovative therapies that improve care, reduce healthcare costs, and provide an amazing experience for patients and their caregivers.&rdquo;</p>\n<h2><strong>$230 million funding to date</strong></h2>\n<p>The financing round brings the company&rsquo;s total equity funding to date to $230 million and further positions Akili to continue leading the industry in delivering on the promise of bringing digital therapeutics to patients. In conjunction with the Series D financing, Akili also closed a credit facility for up to $50 million with&nbsp;Silicon Valley Bank&nbsp;that provides for an optimal capital structure.</p>\n<p>&ldquo;Our $160 million financing announced today is another significant step in delivering on Akili&rsquo;s mission to reinvent medicine,&rdquo; stated Santosh Shanbhag, chief financial officer at Akili. &ldquo;This is the latest milestone in what has been a revolutionary journey for Akili. It will enable us to bring EndeavorRx to as many appropriate patients as possible, advance our core technology, expand our global footprint, and fund research across a wide range of cognitive impairments.&rdquo;</p>", "date": "2021-05-26 16:18:00", "meta_title": "Akili bags $160 million in financing; poised to deliver on digital the", "meta_keywords": "Akili Interactive, EndeavorRx, Equity, Debt, Financing, Series D", "meta_description": "Akili bags $160 million in financing; poised to deliver on digital therapeutics", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-26 16:17:37", "updated": "2021-05-26 16:25:36", "access": NaN, "url": "https://www.thepharmaletter.com/article/akili-bags-160-million-in-financing-poised-to-deliver-on-digital-therapeutics", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "akili_large.png", "image2id": "akili_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Business Financing, Digital Pharma, One to Watch Companies", "geography_tag": "USA", "company_tag": "Akili Interactive, Neuberger berman", "drug_tag": "EndeavorRx", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-26 16:18:00"}